Literature DB >> 15268899

Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.

S G Holmes1, K Still, D J Buttle, N J Bishop, P S Grabowski.   

Abstract

Chemically modified tetracyclines (CMTs) are thought to inhibit bone resorption primarily through their ability to inhibit matrix metalloproteinases (MMPs). We have previously demonstrated that some tetracycline compounds (TCs) induce apoptosis in mature rabbit osteoclasts and inhibit osteoclastic resorption in mouse osteoblast/marrow co-cultures in vitro. In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions. Osteoclast formation over 20 days was completely abrogated when CMT-3 or CMT-8 were included in PBMC cultures at a concentration of 250 ng/ml, although doxycycline at this concentration reduced osteoclast formation to ca. 50% of control. CMT-3 and CMT-8 also significantly induced apoptosis over 24 h in mature osteoclasts generated over 20 days when added to cultures at 5 microg/ml or more. In a time-course experiment, apoptosis was evident after a delay of 1-2 h following treatment of mature osteoclasts with CMT-3 at 20 microg/ml. The broad-spectrum MMP inhibitor BB94 (Batimastat) did not recapitulate the apoptosis induced by CMT-3, even at a concentration where MMP-13 activity was completely inhibited. There was no evidence for an anabolic effect of any of the TCs on osteoblast lineage cells in a calcifying fibroblastic colony (CFU-f) formation assay, where CMT-3 partially inhibited CFU-f formation at 5 microg/ml. Our data indicate that inhibition of osteoclast formation and induction of osteoclast apoptosis are pharmacologically significant actions of CMTs in inhibiting bone resorption, and that osteoclast apoptosis cannot be attributed to the ability of CMTs to inhibit MMPs or to actions mediated by osteoblastic lineage cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15268899     DOI: 10.1016/j.bone.2004.02.028

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  16 in total

1.  Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.

Authors:  Gilson C N Franco; Mikihito Kajiya; Tadashi Nakanishi; Kouji Ohta; Pedro L Rosalen; Francisco C Groppo; Cory W O Ernst; Janie L Boyesen; John D Bartlett; Philip Stashenko; Martin A Taubman; Toshihisa Kawai
Journal:  Exp Cell Res       Date:  2011-03-21       Impact factor: 3.905

Review 2.  Tetracyclines and bone: Unclear actions with potentially lasting effects.

Authors:  Amy J Warner; Jessica D Hathaway-Schrader; Rena Lubker; Christopher Davies; Chad M Novince
Journal:  Bone       Date:  2022-03-03       Impact factor: 4.626

3.  Percutaneous doxycycline treatment of aneurysmal bone cysts with low recurrence rate: a preliminary report.

Authors:  William E Shiels; Joel L Mayerson
Journal:  Clin Orthop Relat Res       Date:  2013-05-14       Impact factor: 4.176

4.  Comparison of osteoclast precursors in peripheral blood mononuclear cells from rheumatoid arthritis and osteoporosis patients.

Authors:  Michinari Nose; Hidetoshi Yamazaki; Hiroshi Hagino; Yasuo Morio; Shin-Ichi Hayashi; Ryota Teshima
Journal:  J Bone Miner Metab       Date:  2008-12-12       Impact factor: 2.626

5.  Black bone disease in a healing fracture.

Authors:  Desmond Thiam; Tse Yean Teo; Rishi Malhotra; Kong Bing Tan; Yu Han Chee
Journal:  BMJ Case Rep       Date:  2016-01-28

6.  Biomaterial-Based Nanocomposite for Osteogenic Repurposing of Doxycycline.

Authors:  Salma El-Habashy; Hoda Eltaher; Ahmed Gaballah; Radwa Mehanna; Amal H El-Kamel
Journal:  Int J Nanomedicine       Date:  2021-02-12

7.  M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts.

Authors:  Jason M Hodge; Fiona M Collier; Nathan J Pavlos; Mark A Kirkland; Geoffrey C Nicholson
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

8.  Chemically modified tetracyclines: Novel therapeutic agents in the management of chronic periodontitis.

Authors:  Rupali Agnihotri; Sumit Gaur
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

Review 9.  Chemically modified tetracyclines: The novel host modulating agents.

Authors:  Devulapalli Narasimha Swamy; Sahitya Sanivarapu; Srinivas Moogla; Vasavi Kapalavai
Journal:  J Indian Soc Periodontol       Date:  2015 Jul-Aug

10.  A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review.

Authors:  M Soory
Journal:  Open Dent J       Date:  2008-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.